Nufarm stock keeps earnings recovery and leverage in focus

Nufarm is heading toward its full-year results with earnings recovery, leverage reduction and cost control at the center of the investor debate. In an analysis published Monday, November 2, 2026, Kalkine cited the company's September outlook and identified the November 19 full-year release as the next major reporting milestone.

Guidance sets the earnings benchmark

Nufarm said on September 23 that it expected underlying EBITDA for fiscal 2026 to increase by approximately 25% from the previous corresponding period. That remains management guidance rather than a reported full-year result. The November release should show how earnings, cash flow and leverage developed against that outlook.

Seed technologies support recovery

Management expects the Seed Technologies division to deliver strong underlying EBITDA growth, with Hybrid Seeds and Omega-3 identified as contributors. Nufarm has also described a strategy refresh focused on simplifying operations, reducing costs and improving returns. These initiatives remain in progress and should be assessed through subsequent operating results rather than treated as completed changes.

Leverage remains a central test

Management expects leverage to decline to approximately 2.0 times, supported by earnings, cash generation and working-capital discipline. Nufarm has also said it is on track to deliver AUD 50 million in run-rate cost savings by the end of fiscal 2027. Both targets are forward-looking and leave execution, cash conversion and balance-sheet progress as key issues for investors.

The real-time quote of Nufarm stock stood at 2.11 euros on Lang & Schwarz at 8:12 p.m. CET on Tuesday, November 3, 2026.

The broader Australian equity market is represented by the S&P/ASX 200.

More news and analyses on Nufarm stock.